Belite Bio (BLTE) News Today → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free BLTE Stock Alerts $44.97 +2.59 (+6.11%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 6:02 AM | americanbankingnews.comBelite Bio (NASDAQ:BLTE) Rating Reiterated by BenchmarkMay 18 at 5:02 AM | americanbankingnews.comFY2024 EPS Estimates for Belite Bio, Inc Cut by Analyst (NASDAQ:BLTE)May 18 at 2:17 AM | americanbankingnews.comHC Wainwright Equities Analysts Reduce Earnings Estimates for Belite Bio, Inc (NASDAQ:BLTE)May 18 at 2:17 AM | americanbankingnews.comLeerink Partnrs Comments on Belite Bio, Inc's Q2 2024 Earnings (NASDAQ:BLTE)May 17 at 8:59 AM | marketbeat.comFY2024 Earnings Estimate for Belite Bio, Inc Issued By Cantor Fitzgerald (NASDAQ:BLTE)Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for Belite Bio in a research note issued to investors on Wednesday, May 15th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings of ($1.04) per sMay 17 at 6:30 AM | americanbankingnews.comBelite Bio (NASDAQ:BLTE) Rating Reiterated by Cantor FitzgeraldMay 17 at 6:30 AM | americanbankingnews.comBelite Bio (NASDAQ:BLTE) Rating Reiterated by HC WainwrightMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. on Strong Clinical Trials and Solid Financial FootingMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Strong Financials and Promising Stargardt Disease Drug ProspectsMay 16, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Receives Buy Rating from BenchmarkBenchmark reissued a "buy" rating and set a $57.00 target price on shares of Belite Bio in a research report on Thursday.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Promising Tinlarebant Trials and Potential Stargardt Disease TreatmentMay 15, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $59.00 price target on shares of Belite Bio in a research note on Wednesday.May 14, 2024 | seekingalpha.comBelite Bio, Inc 2024 Q1 - Results - Earnings Call PresentationMay 14, 2024 | finance.yahoo.comBelite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceMay 14, 2024 | investorplace.comBLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024May 14, 2024 | globenewswire.comBelite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor ConferenceMay 14, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | globenewswire.comBelite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | americanbankingnews.comBelite Bio (BLTE) Scheduled to Post Quarterly Earnings on TuesdayMay 11, 2024 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 44.4% in AprilBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 18,900 shares, a drop of 44.4% from the April 15th total of 34,000 shares. Based on an average daily volume of 40,600 shares, the days-to-cover ratio is presently 0.5 days.May 9, 2024 | marketbeat.comBelite Bio (BLTE) to Release Earnings on TuesdayBelite Bio (NASDAQ:BLTE) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports.May 8, 2024 | globenewswire.comBelite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsMay 6, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Gap Down to $43.20Belite Bio (NASDAQ:BLTE) Shares Gap Down to $43.20May 6, 2024 | globenewswire.comBelite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantMay 6, 2024 | globenewswire.comBelite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingMay 2, 2024 | seekingalpha.comBLTE Belite Bio, IncMay 1, 2024 | globenewswire.comBelite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 28, 2024 | marketbeat.comShort Interest in Belite Bio, Inc (NASDAQ:BLTE) Declines By 13.0%Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 34,000 shares, a decrease of 13.0% from the March 31st total of 39,100 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is presently 0.7 days.April 27, 2024 | investing.comBelite Bio secures $25 million in registered direct offeringApril 25, 2024 | globenewswire.comBelite Bio Announces $25 Million Registered Direct OfferingApril 18, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Trading 6.7% Higher Belite Bio (NASDAQ:BLTE) Shares Up 6.7%April 13, 2024 | morningstar.comBelite Bio Inc ADRApril 12, 2024 | marketbeat.comBelite Bio, Inc (NASDAQ:BLTE) Sees Large Drop in Short InterestBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 39,100 shares, a decline of 34.3% from the March 15th total of 59,500 shares. Based on an average daily volume of 61,400 shares, the days-to-cover ratio is currently 0.6 days.April 9, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Gap Down to $39.98Belite Bio (NASDAQ:BLTE) Shares Gap Down to $39.98April 4, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Down 1.8%Belite Bio (NASDAQ:BLTE) Shares Down 1.8%March 30, 2024 | marketbeat.comShort Interest in Belite Bio, Inc (NASDAQ:BLTE) Grows By 20.7%Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 59,500 shares, a growth of 20.7% from the February 29th total of 49,300 shares. Based on an average daily volume of 74,100 shares, the days-to-cover ratio is presently 0.8 days.March 27, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Shares Down 4.8% Belite Bio (NASDAQ:BLTE) Trading Down 4.8%March 23, 2024 | finanznachrichten.deBelite Bio, Inc: Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 22, 2024 | msn.comBelite Retreats On Start Of Clinical TrialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Belite Bio as Tinlarebant Shows Promising Clinical Advancements and Market PotentialMarch 22, 2024 | marketbeat.comBelite Bio's (BLTE) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $59.00 target price on shares of Belite Bio in a research report on Friday.March 22, 2024 | globenewswire.comBelite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanMarch 21, 2024 | markets.businessinsider.comBuy Rating Justified for Belite Bio, Inc. ADR Amidst Promising DRAGON Trial Progress and Strong FinancialsMarch 21, 2024 | marketbeat.comBelite Bio, Inc Expected to Post Q1 2024 Earnings of ($0.40) Per Share (NASDAQ:BLTE)Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Belite Bio in a note issued to investors on Monday, March 18th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings per shareMarch 20, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn SituationMarch 20, 2024 | marketbeat.comBelite Bio, Inc to Post FY2028 Earnings of $4.45 Per Share, Leerink Partnrs Forecasts (NASDAQ:BLTE)Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at Leerink Partnrs cut their FY2028 earnings per share estimates for Belite Bio in a research note issued on Monday, March 18th. Leerink Partnrs analyst M. Goodman now expects that the company will earn $4.45 per share for the yearMarch 19, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Trading 5.9% Higher Belite Bio (NASDAQ:BLTE) Trading Up 5.9%March 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)March 14, 2024 | nasdaq.comBelite Bio is Now Oversold (BLTE) Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs BLTE Media Mentions By Week BLTE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLTE News Sentiment▼0.180.42▲Average Medical News Sentiment BLTE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLTE Articles This Week▼322▲BLTE Articles Average Week Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MNKD News XNCR News MIRM News ABCL News ELVN News PRTA News GYRE News VRNA News COLL News GMTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLTE) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
